Human Mass Balance and Metabolite Profiling of [<SUP>14</SUP>C]-Pamiparib, a Poly (ADP-Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer



Mu, Song, Palmer, Daniel ORCID: 0000-0002-7147-5703, Fitzgerald, Richard, Andreu-Vieyra, Claudia, Zhang, Heather, Tang, Zhiyu, Su, Dan and Sahasranaman, Srikumar
(2021) Human Mass Balance and Metabolite Profiling of [<SUP>14</SUP>C]-Pamiparib, a Poly (ADP-Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 10 (9). pp. 1108-1120.

Access the full-text of this item by clicking on the Open Access link.

Abstract

Pamiparib, a selective poly (ADP-ribose) polymerase 1/2 inhibitor, demonstrated tolerability and antitumor activity in patients with solid tumors at 60 mg orally twice daily. This phase 1 open-label study (NCT03991494; BGB-290-106) investigated the absorption, metabolism, and excretion (AME) of 60 mg [<sup>14</sup> C]-pamiparib in 4 patients with solid tumors. The mass balance in excreta, blood, and plasma radioactivity and plasma pamiparib concentration were determined along with metabolite profiles in plasma, urine, and feces. Unchanged pamiparib accounted for the most plasma radioactivity (67.2% ± 10.2%). Pamiparib was rapidly absorbed with a median time to maximum plasma concentration (C<sub>max</sub> ) of 2.00 hours (range, 1.00-3.05 hours). After reaching C<sub>max</sub> , pamiparib declined in a biphasic manner, with a geometric mean terminal half-life (t<sub>1/2</sub> ) of 28.7 hours. Mean cumulative [<sup>14</sup> C]-pamiparib excretion was 84.7% ± 3.5%. Pamiparib was mainly cleared through metabolism, primarily via N-oxidation and oxidation of the pyrrolidine ring. A dehydrogenated oxidative product (M3) was the most abundant metabolite in biosamples. A mean of 2.11% and 1.11% of [<sup>14</sup> C]-pamiparib was excreted as unchanged pamiparib in feces and urine, respectively, indicating near-complete absorption and low renal clearance of parent drug. Cytochrome P450 (CYP) phenotyping demonstrated CYP2C8 and CYP3A involvement in pamiparib metabolism. These findings provide an understanding of pamiparib AME mechanisms and potential drug-drug interaction liability.

Item Type: Article
Uncontrolled Keywords: absorption, metabolism, excretion, DNA repair, metabolite identification, pamiparib, pharmacokinetics
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 11 May 2021 10:25
Last Modified: 18 Oct 2023 09:45
DOI: 10.1002/cpdd.943
Open Access URL: https://doi.org/10.1002/cpdd.943
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3122325